These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

839 related items for PubMed ID: 26385220

  • 21. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.
    Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
    [Abstract] [Full Text] [Related]

  • 22. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 23. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A.
    Arthritis Care Res (Hoboken); 2017 Jan 20; 69(1):115-123. PubMed ID: 27390293
    [Abstract] [Full Text] [Related]

  • 24. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG, Fusco BE.
    Clin Ther; 2012 May 20; 34(5):1006-22. PubMed ID: 22464040
    [Abstract] [Full Text] [Related]

  • 25. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.
    Mod Rheumatol; 2020 Mar 20; 30(2):313-320. PubMed ID: 31199180
    [Abstract] [Full Text] [Related]

  • 26. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.
    Ann Rheum Dis; 2008 Jul 20; 67(7):1011-6. PubMed ID: 17962238
    [Abstract] [Full Text] [Related]

  • 27. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B.
    Arthritis Rheumatol; 2022 Jan 20; 74(1):112-123. PubMed ID: 34164944
    [Abstract] [Full Text] [Related]

  • 28. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, BLISS-52 and BLISS-76 Study Groups.
    Ann Rheum Dis; 2012 Nov 20; 71(11):1833-8. PubMed ID: 22550315
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH, Wiens A, de Souza TT, Correr CJ, Pontarolo R.
    BioDrugs; 2014 Apr 20; 28(2):211-28. PubMed ID: 24190520
    [Abstract] [Full Text] [Related]

  • 30. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
    Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M.
    Ann Rheum Dis; 2019 May 20; 78(5):629-633. PubMed ID: 30679152
    [Abstract] [Full Text] [Related]

  • 31. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS.
    Ann Rheum Dis; 2018 Jun 20; 77(6):883-889. PubMed ID: 29563108
    [Abstract] [Full Text] [Related]

  • 32. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP, D'Cruz DP.
    Expert Opin Drug Metab Toxicol; 2015 Jun 20; 11(10):1635-45. PubMed ID: 26327145
    [Abstract] [Full Text] [Related]

  • 33. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, Hahne M, Combe B.
    Ann Rheum Dis; 2009 Jun 20; 68(6):997-1002. PubMed ID: 18676986
    [Abstract] [Full Text] [Related]

  • 34. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2170-2176. PubMed ID: 31157891
    [Abstract] [Full Text] [Related]

  • 35. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE, BLISS-52 and -76 Study Groups.
    Ann Rheum Dis; 2014 May 01; 73(5):838-44. PubMed ID: 23524886
    [Abstract] [Full Text] [Related]

  • 36. Belimumab: targeted therapy for lupus.
    Chugh PK, Kalra BS.
    Int J Rheum Dis; 2013 Feb 01; 16(1):4-13. PubMed ID: 23441766
    [Abstract] [Full Text] [Related]

  • 37. Anti-BLyS Treatment of 36 Israeli Systemic Lupus Erythematosus Patients.
    Sthoeger Z, Lorber M, Tal Y, Toubi E, Amital H, Kivity S, Langevitz P, Asher I, Elbirt D, Agmon Levin N.
    Isr Med Assoc J; 2017 Jan 01; 19(1):44-48. PubMed ID: 28457114
    [Abstract] [Full Text] [Related]

  • 38. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Belimumab Study Group.
    Arthritis Res Ther; 2008 Jan 01; 10(5):R109. PubMed ID: 18786258
    [Abstract] [Full Text] [Related]

  • 39. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA, PEARL-SC Study.
    Ann Rheum Dis; 2015 Sep 01; 74(9):1667-75. PubMed ID: 24748629
    [Abstract] [Full Text] [Related]

  • 40. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
    Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I.
    Autoimmun Rev; 2017 Apr 01; 16(4):343-351. PubMed ID: 28216072
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.